Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Lee, Eudocia Q. , Khasraw, Mustafa , Rahman, Rifaquat , Platten, Michael , Lim, Michael , Verhaak, Roel G.W. , Albert, Nathalie L. , Schiff, David , Ostrom, Quinn T. , Aldape, Kenneth , Batchelor, Tracy T. , Chiocca, E. Antonio, DeGroot, John, French, Pim J. , Hegi, Monika E. , Lassman, Andrew B. , Mellinghoff, Ingo K. , Minniti, Giuseppe, Taphoorn, Martin , Weiss, von Deimling, Tobias, Zadeh, Gelareh , Reardon, David A. , Chang, Susan M. , Short, Susan , Weller, Michael , Touat, Mehdi , Khasraw, Mustafa , Platten, Michael , Winkler, Frank , Verhaak, Roel Gw , Albert, Nathalie L , Tonn, Joerg-Christian , Barnholtz-Sloan, Jill S , Cloughesy, Timothy F , French, Pim J , Galanis, Evanthia , Galldiks, Norbert , Mellinghoff, Ingo K , Roth, Patrick , Sanson, Marc , Wick, Wolfgang , Reardon, David A , Short, Susan C , Ostrom, Quinn T , Wen, Patrick Yung , Horbinski, Craig , Huang, Raymond Y. , Ahluwalia, Manmeet S. , Barnholtz‐Sloan, Jill S. , Bindra, Ranjit S. , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Rhun, Émilie Le , Mehta, Minesh P. , Roth, Patrick , Sanson, Marc , Weiss, von Deimling, Tobias, Wick, Wolfgang , Bent, Martin J. van den , Preusser, Matthias

Neuro-Oncology | July 22, 2025 | Volume: 27 | Issue: 11 | Pages: 2751-2788

10.1093/neuonc/noaf177 | PMID 40827022 Get It

Abstract Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody–drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Evaluating Updated Fentanyl Immunoassays for Loperamide Interference
Walsh, Michael , Williams, Grace R , Jannetto, Paul J. , Walsh, Michael E , Geno, K Aaron , Geno, K. Aaron

The Journal of Applied Laboratory Medicine | July 22, 2025 | Volume: 10 | Issue: 6 | Pages: 1607-1613

10.1093/jalm/jfaf110 | PMID 40833796 Get It

Abstract Background Loperamide is a µ-opioid receptor agonist that reduces intestinal peristalsis and is used to treat diarrhea. We previously described significant cross-reactivity of loperamide with 2 fentanyl immunoassays. Since then, new fentanyl immunoassays, including a CLIA-waived point-of-care device, have been approved for clinical use. Methods We evaluated new fentanyl immunoassays for cross-reactivity to loperamide and its major metabolites, N-desmethyl loperamide (dLop) and N-didesmethyl loperamide (ddLop). Previously characterized assays were tested for cross-reactivity to ddLop, which recently became commercially available. Loperamide, dLop, and ddLop were spiked in drug-free urine for analysis by 5 enzyme immunoassays run on automated chemistry analyzers and one lateral flow assay for the detection of fentanyl. Results Loperamide and its metabolites produced positive results in 3 fentanyl immunoassays. The Immunalysis HEIA was previously determined to be reactive to both loperamide and dLop, but it was not reactive to ddLop. The Immunalysis SEFRIA was reactive to loperamide, dLop, and ddLop at minimum concentrations of 14.7 mg/L, 13.1 mg/L, and 17.0 mg/L. The Thermo Fisher DRI was previously determined to be reactive to loperamide and dLop, and it was reactive to ddLop at a minimum concentration of 33.1 mg/L. The Abbott iCassette, ARK Fentanyl II, and Lin-Zhi LZI II fentanyl assays showed no cross-reactivity to loperamide or its metabolites. Conclusions The cross-reactivity of loperamide, dLop, and ddLop in several fentanyl immunoassays has the potential to cause false-positive results during urine drug screening.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines
Carcinomatosis, Expert Panel Management of Peritoneal, Kennedy, Timothy J., Singh, Sareena , Abood, Gerard, Anker, Christopher J. , Akselrod, Dmitriy , Hallemeier, Christopher L. , Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Small, William , Russo, Suzanne , Carcinomatosis, Expert Panel Management of Peritoneal, Christenson, Eric, Jethwa, Krishan R. , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Tchelebi, Leila T.

Cancer Medicine | July 22, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1002/cam4.71043 | PMID 40693544 Get It

ABSTRACT Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin. Aims To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence. Materials and Methods The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology. Results Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary. Discussion Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios. Conclusion A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.
Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
Hossain, Nasheed , Ahn, Kwang Woo , Patel, Jinalben , Lian, Qinghua, Abid, Muhammad Bilal , Nughmush, Ahmed Al, Bi, Xia , Hashmi, Shahrukh K. , Hilal, Talal , Modi, Dipenkumar , Rizzieri, David A. , Steinberg, Amir , Vij, Ravi, Herrera, Alex F. , Hossain, Nasheed M , Abid, Muhammad Bilal , Bacher, Ulrike , Hilal, Talal , Modi, Dipenkumar , Hamadani, Mehdi , Herrera, Alex F , Husnain, Muhammad , Khimani, Farhad , Maziarz, Richard Thomas , Ram, Ron , Sica, Roberto Alejandro , Shadman, Mazyar , Turtle, Cameron J. , Hamadani, Mehdi

British Journal of Haematology | July 22, 2025 | Volume: 207 | Issue: 3 | Pages: 1011-1018

10.1111/bjh.70020 | PMID 40693472 Get It

Summary CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy is a pivotal part of the treatment algorithm for large B‐cell lymphoma (LBCL) in the second‐ and third‐line settings based on numerous clinical trials. However, these studies included very few patients with a diagnosis of high‐grade B‐cell lymphoma, not otherwise specified (HGBCL‐NOS) and it is unclear if outcomes are similar to those observed with more common LBCL histologies. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we identified 111 HGBCL‐NOS patients who received CAR‐T therapy. The cytokine release syndrome (CRS) rate was 74% (7.7% grade 3+), median onset was 4 days (1–17) and immune effector cell‐associated neurotoxicity syndrome rate was 45.2% (22.6% grade 3+), median onset was 7 days (1–17). At 2 years post‐CAR‐T infusion, the probability of overall survival and progression‐free survival were 41.6% and 28.7% respectively. The 2‐year non‐relapse mortality and relapse/progression were 3.1% (95% confidence interval [CI]: 0.6–7.6) and 68.1% (95% CI: 57.9–77.6) respectively. Our analysis illustrates that patients with HGBCL‐NOS represent a particularly difficult group to treat, even with CAR‐T therapy. We observed that one third of patients achieved a durable response; however, the overall results were less favourable, with lower overall response rate, overall survival and progression‐free survival as compared to published reports on LBCL.
ASRA Pain Medicine Consensus Practice Infection Control guidelines
Provenzano, David , Hunt, Christine , Kalagara, Hari , Uppal, Vishal , Provenzano, David Anthony , Uppal, Vishal , Hunt, Christine , Kalagara, Hari

Regional Anesthesia & Pain Medicine | July 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-106770

10.1136/rapm-2025-106770 | PMID 40695539 Get It

What Is the Appropriate Sample Size in Human Cadaveric Studies? A Quantitative Review of 770 Articles
Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R. , Kikuchi, Keishiro, Kim, Chung Yoh , Ono, Kisho , D'Antoni, Anthony, Komune, Noritaka , Kitagawa, Norio , Kim, Hee‐Jin , Loukas, Marios , Watanabe, Koichi , Tubbs, R. Shane , Iwanaga, Joe , Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R , Kim, Chung Yoh , Ono, Kisho , Komune, Noritaka , Tabira, Yoko , Hur, Mi-Sun , Kim, Hee-Jin , Loukas, Marios , Watanabe, Koichi , Iwanaga, Joe , Cardona, Juan J. , Kikuchi, Keishiro , D’Antoni, Anthony V. , Tabira, Yoko

Clinical Anatomy | July 22, 2025 | Volume: 39 | Issue: 1 | Pages: 14-19

10.1002/ca.70007 | PMID 40692167 Get It

ABSTRACT Determining an appropriate sample size in human cadaveric studies remains a long‐standing and unresolved challenge. Unlike other basic science fields, anatomical research is constrained by factors such as limited human donor availability, cultural considerations, and ethical restrictions. Despite these limitations, researchers are often asked to justify sample sizes, yet no standardized guidelines currently exist. To quantitatively assess sample sizes in recent human cadaveric studies and propose evidence‐based recommendations for future research, a PubMed search was conducted on February 26, 2024, using the term human cadaveric study . The articles published in 2023 and 2024 were screened, yielding 770 eligible studies. Data extracted included the total sample size, number of classified groups, and journal impact factor (IF). Descriptive statistics, linear regression, and correlation analyses were performed. Continuous variables were summarized using medians and interquartile ranges (IQR). The median sample size was 11.5 (IQR: 7–20), and 47.9% of studies used 10 or fewer specimens. The median number of classified groups was 3 (IQR: 2–4). Linear regression showed that studies dividing specimens into 2–6 groups often failed to meet the recommended sample size per group based on regression modeling. No significant correlation was found between sample size and journal IF ( r = −0.062, p = 0.115). Most cadaveric studies rely on small sample sizes due to inherent constraints, yet many still attempt a subgroup analysis without sufficient statistical power. Although flexibility is essential in anatomical research, we recommend a minimum total sample size of 10 for basic studies and at least five samples per group for those involving classification. Cadaveric sample size alone does not predict journal impact, highlighting the importance of methodological rigor over quantity.
Una revisión de las reparaciones artroscópicas del complejo volar escafosemilunar
Chung, Sze Ryn , Kakar, Sanjeev , Kakar, Sanjeev

Revista Iberoamericana de Cirugía de la Mano | July 21, 2025 | Volume: 53 | Issue: 01 | Pages: e13-e24

10.1055/s-0045-1809557 Get It

ResumenSi bien el papel del complejos volar escafolunar en la estabilidad de la muñeca es cada vez más reconocido la literatura sobre sus técnicas de reparación y resultados sigue siendo limitada. Este artículo ofrece una visión general completa de la anatomía la biomecánica y la importancia clínica del complejo escafolunar volar junto con las técnicas de reparación artroscópica más actualizadas. Al presentar los avances y los desafíos de estos abordajes mínimamente invasivos buscamos fomentar la investigación y el desarrollo para abordar este aspecto aunque poco reconocido crucial de la inestabilidad escafolunar.
Do Extracellular Vesicles Mediate the Muscle Insulin Resistance of Obesity and Type 2 Diabetes?
Lytle, Kelli A. , Jensen, Michael D.

Diabetes Care | July 21, 2025 | Volume: 48 | Issue: 8 | Pages: 1315-1317

10.2337/dci25-0039 | PMID 40690653 Get It

Validity and Reliability of the Observed Structured Point of Care Ultrasound Readiness Examination (OSPRE): A Pilot Study
Breunig, Mike, Kingsley, Ryan , Galush, Tiffany, Ragaisis, Taryn, Boldenow, Laura, Schouten, Will M. , Kashiwagi, Deanne T. , Breunig, Mike

No container title available | July 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7011397/v1 Get It

Abstract Background In the context of competency-based medical education, more research is needed to define point-of-care ultrasound (POCUS) competency and validate learner assessment. To address noted gaps in the currently validated assessment instruments, we developed the Observed Structured POCUS Readiness Examination (OSPRE). The purpose of this study is to demonstrate evidence of validity and reliability of the OSPRE in Physician Assistant (PA) students. Methods A prospective cohort study was designed to demonstrate evidence of validity and reliability for the OSPRE instrument at one PA program. Students completed a hands-on skills assessment utilizing a simulated patient scenario involving a traumatic injury. Student performance was assessed in real time by one reviewer and asynchronously by a second reviewer blinded to the scoring of the initial reviewer. Inter-rater reliability was calculated for overall score and for each criterion of the OSPRE. Results Intraclass correlation coefficient for the final percentage score between the independent reviewers utilizing the OSPRE instrument was noted to be 0.86 (95% CI 0.56–0.95, p < 0.001), demonstrating overall good reliability. Level of agreement for inter-rater reliability for the specific individual criterion ranged between fair and substantial. Conclusion The OSPRE instrument provides a valid and reliable assessment of POCUS skills in PA students. When compared to previously validated assessment instruments, scores on the OSPRE had a wider range, suggesting that the OSPRE might have a greater discriminatory value for POCUS skillset.